International HIT-MED Registry (I-HIT-MED)

Recruiting now

Conditions studied: Childhood Brain Tumor

In brief

The I-HIT-MED registry registers clinical of children and adults with medulloblastoma, ependymoma, pineal tumours, or choroid plexus tumours in Germany and other countries that fulfil national ethic requirements for participation in this registry. These tumours are rare diseases, and many patients are treated outside of clinical trials. The I-HIT-MED registry allows collection of data und biological material from those patients, and provides a basis for standard treatment recommendations and counselling. It aims to improve the international cooperation and the medical knowledge in these rare diseases. Within the I-HIT-MED registry, it is a goal to maintain and improve networks for quality assurance in national groups where they are already established, and to support the implementation in national groups, where there is no quality assurance network yet.

Key facts

Study ID

NCT02417324

Run by

Universitätsklinikum Hamburg-Eppendorf

People needed

500

Starts

2015-01-01

Expected to finish

2029-12-01

Last updated by the study team

2025-12-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• all patients with above mentioned diagnosis of all ages (except for ependymoma WHO I°, pineal parenchymal tumour of intermediate differentiation and papillary tumour of the pineal region, who will be registered only if primary diagnosis was before the 18th birthday)
• any localisation of the primary tumour
• all clinical stages
• First diagnosis after 01.01.2012
• No inclusion into a prospective clinical trial for the same diagnosis, due to non-eligibility, national lack of trial approval, or individual refusal of participation.
• Written informed consent for data transfer and tumour sample submission according to the laws of each participating country is necessary.
• National and/ or local ethical committee approval according to the laws of each participating country is necessary.

You may not qualify if…

• Registration in another clinical trial for the same diagnosis (relapse is defined as a second diagnosis).
• Lack of valid ethical committee approval.

Where it is running

• Medizinische Hochschule Hannover — Hanover, Germany (enrolling)
• Angelika-Lautenschläger-Klinik — Heidelberg, Germany (enrolling)
• Klinikum Augsburg — Augsburg, Germany (enrolling)
• University Hospital Aachen — Aachen, Germany (enrolling)
• Klinikum Braunschweig — Braunschweig, Germany (enrolling)
• Helios Klinikum Berlin-Buch — Berlin, Germany (enrolling)
• Klinikum Chemnitz — Chemnitz, Germany (enrolling)
• Charite Campus, University of Berlin — Berlin, Germany (enrolling)
• Carl-Thiem-Klinikum Cottbus — Cottbus, Germany (enrolling)
• Evangelisches Krankenhaus Bielefeld — Bielefeld, Germany (enrolling)
• Klinikum Dortmund — Dortmund, Germany (enrolling)
• University Hospital Dresden — Dresden, Germany (enrolling)
• Klinikum Bremen-Mitte — Bremen, Germany (enrolling)
• Universitäts-Kinderklinik Düsseldorf — Düsseldorf, Germany (enrolling)
• HELIOS Klinikum-Erfurt — Erfurt, Germany (enrolling)
• University Hospital Erlangen — Erlangen, Germany (enrolling)
• University Hospital Essen — Essen, Germany (enrolling)
• University Hospital Frankfurt/Main — Frankfurt, Germany (enrolling)
• University Hospital Freiburg — Freiburg im Breisgau, Germany (enrolling)
• Universitätsklinikum Gießen und Marburg — Giessen, Germany (enrolling)
• Georg-August-Universität Göttingen — Göttingen, Germany (enrolling)
• University Hospital Greifswald — Greifswald, Germany (enrolling)
• University Hospital Halle/Saale — Halle, Germany (enrolling)
• University Medical Center Hamburg-Eppendorf — Hamburg, Germany (enrolling)
• SLK-Kliniken — Heilbronn, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.